Literature DB >> 3436995

Whole blood serotonin in autistic and normal subjects.

G M Anderson1, D X Freedman, D J Cohen, F R Volkmar, E L Hoder, P McPhedran, R B Minderaa, C R Hansen, J G Young.   

Abstract

Whole blood serotonin and tryptophan were measured in 87 normal subjects and in 40 autistic subjects. Whole blood serotonin concentrations (mean +/- SE) were significantly higher in drug-free (N = 21) autistics (205 +/- 16 ng/ml) than in normals (136 +/- 5.4 ng/ml). The Gaussian distribution of serotonin levels in the unmedicated autistic group suggests the elevation was not due to a subgroup of autistic subjects. Autistics medicated with anticonvulsants or neuroleptics had significantly lower serotonin levels than did drug-free autistic subjects. Whole blood tryptophan levels and platelet counts were similar in the autistic and normal groups. The possible causes of the hyperserotonemia of autism are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3436995     DOI: 10.1111/j.1469-7610.1987.tb00677.x

Source DB:  PubMed          Journal:  J Child Psychol Psychiatry        ISSN: 0021-9630            Impact factor:   8.982


  64 in total

Review 1.  Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology.

Authors:  L E Arnold; M G Aman; A Martin; A Collier-Crespin; B Vitiello; E Tierney; R Asarnow; F Bell-Bradshaw; B J Freeman; P Gates-Ulanet; A Klin; J T McCracken; C J McDougle; J J McGough; D J Posey; L Scahill; N B Swiezy; L Ritz; F Volkmar
Journal:  J Autism Dev Disord       Date:  2000-04

2.  Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism.

Authors:  Yoko Sugie; Hideo Sugie; Tokiko Fukuda; Masataka Ito; Yumiko Sasada; Mutsumi Nakabayashi; Kazunobu Fukashiro; Takehiko Ohzeki
Journal:  J Autism Dev Disord       Date:  2005-06

3.  Platelet serotonin, a possible marker for familial autism.

Authors:  J Piven; G C Tsai; E Nehme; J T Coyle; G A Chase; S E Folstein
Journal:  J Autism Dev Disord       Date:  1991-03

4.  Utilization of lymphoblastoid cell lines as a system for the molecular modeling of autism.

Authors:  Colin A Baron; Stephenie Y Liu; Chindo Hicks; Jeffrey P Gregg
Journal:  J Autism Dev Disord       Date:  2006-11

5.  Is there sexual dimorphism of hyperserotonemia in autism spectrum disorder?

Authors:  Lauren C Shuffrey; Stephen J Guter; Shannon Delaney; Suma Jacob; George M Anderson; James S Sutcliffe; Edwin H Cook; Jeremy Veenstra-VanderWeele
Journal:  Autism Res       Date:  2017-04-12       Impact factor: 5.216

6.  Inflammation-induced catabolism of tryptophan and tyrosine in acute ischemic stroke.

Authors:  Heidi Ormstad; Robert Verkerk; Hans Christian D Aass; Karl-Friedrich Amthor; Leiv Sandvik
Journal:  J Mol Neurosci       Date:  2013-08-30       Impact factor: 3.444

Review 7.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

8.  The minicolumnopathy of autism: A link between migraine and gastrointestinal symptoms.

Authors:  Manuel F Casanova
Journal:  Med Hypotheses       Date:  2007-06-14       Impact factor: 1.538

9.  Whole blood serotonin and tryptophan in autism: temporal stability and the effects of medication.

Authors:  R B Minderaa; G M Anderson; F R Volkmar; D Harcherick; G W Akkerhuis; D J Cohen
Journal:  J Autism Dev Disord       Date:  1989-03

10.  In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder.

Authors:  Nicole B Gidaya; Brian K Lee; Igor Burstyn; Michael Yudell; Erik L Mortensen; Craig J Newschaffer
Journal:  J Autism Dev Disord       Date:  2014-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.